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Abstract
Background: Various cutaneous toxicities under chemotherapy indicate a local ef-
fect of chemotherapy by secretion after systemic application. Here, changes in the 
fluorescence and Raman spectral properties of the stratum corneum subsequent to 
intravenous chemotherapy were assessed.
Methods: Twenty healthy subjects and 20 cancer patients undergoing chemotherapy 
were included. Measurement time points in cancer patients were before the first 
cycle of chemotherapy (Tbase) and immediately after intravenous application of the 
chemotherapy (T1). Healthy subjects were measured once without any further inter-
vention. Measurements were conducted using an individually manufactured system 
consisting of a handheld probe and a wavelength-tunable diode laser-based 488 nm 
SHG light source. Hereby, changes in both skin fluorescence and shifted excita-
tion resonance Raman difference spectroscopy (SERRDS) carotenoid signals were 
assessed.
Results: Healthy subjects showed significantly (P < .001) higher mean concentrations 
of carotenoids compared to cancer subjects at Tbase. An increase in fluorescence in-
tensity was detected in almost all patients after chemotherapy, especially after doxo-
rubicin infusion. Furthermore, a decrease in the carotenoid concentration in the skin 
after chemotherapy was found.
Conclusion: The SERRDS based noninvasive detection can be used as an indirect 
quantitative assessment of fluorescent chemotherapeutics. The lower carotenoid 
SERRDS intensities at Tbase might be due to cancerous diseases and co-medication.
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carotenoids, chemotherapy, fluorescence, Raman difference spectroscopy, shifted excitation 
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1  | INTRODUC TION
Cutaneous toxicities count to the most frequent side effects during 
chemotherapy.1,2 Previous studies showed that intravenously applied 
chemotherapeutics can be found within the sweat being secreted to 
the skin surface. The chemotherapeutics subsequently spread on the 
skin surface as if topically applied and re-penetrate into the upper skin 
layers.3 Here, they can lead to radical formation and inflammatory or 
toxic skin effects, including development of palmar-plantar erythrody-
saesthesia, also known as a hand-foot syndrome.4-10
The skin of healthy volunteers, especially the stratum corneum 
layer, usually contains a high concentration of antioxidants. Among 
them are carotenoids, vitamins, and enzymes, which form an antiox-
idant network and serve as a part of the body's protective system 
against free radicals. Recent studies show that carotenoids serve as 
marker substances of the entire antioxidant status of the epidermis 
in vivo11,12 and the kinetics of their degradation in the skin show the 
intensity of influencing stress factors.13
The kinetics of inverse penetration of doxorubicin on the skin 
surface were described previously.3 It was found that 30 minutes to 
1 hour after systemic administration after chemotherapeutic infu-
sion, fluorescence signals of doxorubicin were detectable on the skin 
surface.3 This leads to the conclusion that doxorubicin, like carot-
enoids and vitamin E, too, is secreted to the skin surface with the 
sweat, spreads there, and then penetrates into the stratum corneum 
like topically applied.14 This result also explains why the dermal side 
effects associated with systemic administration of doxorubicin occur 
mainly in the palms of the hands and the soles of the feet. The high-
est sweat gland density is present at these skin sites15 so that the 
proportion of escaping doxorubicin is highest here as well. The horny 
layer is ten to twenty times thicker on the palms and soles of the feet 
than on the other areas of the skin, providing an ideal reservoir for 
the absorption of sweat-derived substances, such as chemothera-
peutics in human skin. Depending on the designated chemotherapy 
schedule and dose, multiple cycles of chemotherapy can cause an 
accumulation of chemotherapeutic substances16 resolving in toxic 
local effects on the skin. However, the specific quantities and dy-
namics for different chemotherapeutics are not fully understood.17
Many chemotherapeutics are Raman-active substances, but their 
direct detection on the skin is hardly possible due to their low con-
centration and superposition with the skin Raman spectrum.18,19 In the 
case of doxorubicin, absorption bands in the range of 440-520 nm20 
and fluorescence in the range of 520-630 nm21 are known. This means 
that the excitation around 488 nm resonantly excites not only the ca-
rotenoids beta-carotene and lycopene22 but also a doxorubicin fluo-
rescence signal23,24 in the skin. Thus, on the one hand, the doxorubicin 
fluorescent signal acts as a background signal for the Raman signal. 
On the other hand, this fluorescent signal makes it possible to detect 
doxorubicin very sensitively in human skin under in vivo conditions.
Noninvasive reflection spectroscopy was used in a previous 
study to investigate the decrease in cutaneous carotenoids as a 
result of increased skin radical formation following intravenous ad-
ministration of chemotherapeutic agents to the patient's palms. The 
results clearly showed the significant decrease in cutaneous carot-
enoids in all intravenously administered chemotherapeutic agents.25 
This clear decrease is detectable using even less sensitive techniques 
such as reflection spectroscopy.22 Therefore, a novel diagnostic sys-
tem would be not only of great importance for the direct detection 
of doxorubicin on the skin but also for indirect detection of a whole 
range of other chemotherapeutic agents by measuring their influ-
ence on cutaneous carotenoids.
In order to be able to quantitatively determine small changes in the 
Raman signal intensity of cutaneous carotenoids in vivo, a fluorescence 
background subtraction procedure should be performed. This can be 
done by taking advantage of the fluorescence photo-bleaching effect 
by prolonged exposure of the skin with the reference light.26 However, 
this method is time-consuming and did not provide complete subtrac-
tion of the fluorescence background.27 A further method is shifted 
excitation resonance Raman difference spectroscopy (SERRDS), which 
provides changes of the excitation wavelength by about 0.4 nm, so that 
the Raman signals shift along with the excitation wavelength, while the 
fluorescence bands remain almost constant. By subtracting the two 
recorded spectra from each other, the fluorescence background is ef-
fectively subtracted, and the carotenoid concentration can then be de-
termined by integrating the corresponding Raman bands. The SERRDS 
device optimized for in vivo measurements of carotenoids in human 
skin was recently developed by the Ferdinand-Braun-Institute28 with 
support of the Einstein Foundation.
Here, changes in the fluorescence and SERRDS signal intensities 
before and after intravenous chemotherapy were assessed in vivo in 
cancer patients.
The assessments within this study aimed at determining changes 
in the carotenoid concentration of the skin as well as detecting dif-
ferent chemotherapeutics by fluorescence changes after intrave-
nous application.
2  | MATERIAL S AND METHODS
2.1 | Measurement system
A miniaturized measurement system based on SERRDS28 was used for 
the assessment of changes in cutaneous carotenoids and fluorescence 
signals on the skin surface in vivo. The system uses a measuring spot 
diameter of 3 mm and a diode laser-based 488 nm SHG light source 
providing two excitation wavelengths λ1 = 487.2 nm and λ2 = 487.6 nm. 
Here, the fluorescence background can be separated from the Raman 
peaks. The system was calibrated to a detection limit of 0.03 nmol g−1 
beta-carotene per gram of skin and was described in detail previously.28 
The carotenoids' signal was recognizable at approx. 1525 cm−1.22
2.2 | Study design
A total of 20 healthy subjects and 20 cancer subjects aged from 
43 to 77 were enrolled in the study, with each subject group 
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including 10 male and 10 female subjects of skin type I-III. Cancer 
subjects suffered from pancreatic carcinoma (25%), mamma carci-
noma (15%), non-Hodgkin's lymphoma (10%), liposarcoma (10%), 
rhabdomyosarcoma (5%), prostate cancer (5%), multiple myeloma 
(5%), hypopharyngeal carcinoma (5%), and adenocarcinoma of the 
ovary (5%) and of the cecum (5%) and metastatic adenocarcinoma 
of unknown primary (5%). The chemotherapies included (pe-
gylated liposomal-) doxorubicin, epirubicin, dacarbacin, vincristin, 
cycloposphamid, Ifosphamid, topotecan, irinotecan, 5-fluoroura-
cil, (nab-)paclitaxel, docetaxel, carboplatin, and gemcitabine and 
were applied in an ambulant setting. The patient-related applied 
chemotherapeutics are summarized in Table 1. All subjects did 
not receive any chemotherapy within the last 4 weeks prior to the 
Tbase measurements. The main exclusion criteria were any type of 
cutaneous toxicity, eczema, or other relevant skin disease within 
the measurement area.
Measurements in cancer subjects were taken once before sys-
temic intravenous administration (Tbase) of the chemotherapeutic 
agent and a second time immediately after systemic administration 
of the chemotherapy (T1). The measurements were carried out on 
both palms at each thenar eminence with five measurements per 
time point and measuring area.
Healthy subjects were measured at one time point without any 
further intervention and measurement data compared to those of 
cancer subjects at Tbase.
Subsequently, the measured Raman spectra were analyzed 
for measurement quality and the presence of carotenoid-related 
Raman bands. The corresponding SERRDS intensity was calculated 
by integrating the Raman signals around the peak at 1525 cm−1 at 
an excitation wavelength of 487.2 and 487.6 nm and was used for 
the assessment of carotenoid concentration in the skin. The mean 
of the SERRDS intensities of all measurements from one mea-
surement area was calculated. In addition to the SERRDS results, 
the fluorescence intensity at identical position (peak at 526.3 nm: 
excitation wavelength 487.2 nm, Raman shift 1525 cm−1) was 
calculated.
The applied chemotherapeutics in 18 out of 20 patients could be 
divided into two major groups according to their main active ingredi-
ents, on the one hand, active ingredients from the group of anthracy-
clines and on the other hand, the active ingredients from the group 
of alkaloids (Table 1). Two patients received both anthracyclines and 
alkaloids. This assignment was used in parts of the evaluation.
2.3 | Ethical approval
Prior to initiation of the study, approval by the independent Ethics 
Committee of the State Office of Health and Social Affairs Berlin 
(LaGeSo) was obtained. The study was registered at the European 
Databank on Medical Devices (Eudamed No. CIV 15-03-013265) 
and was conducted according to the principles of the Declaration 
of Helsinki (1996) and Good Clinical Practice Guidelines. All subjects 
provided written informed consent.
2.4 | Statistical analysis
The descriptive and statistical analysis of the obtained data was con-
ducted using IBM SPSS vs 22. Analysis of SERRDS values was sub-
ject to Mann-Whitney U test, in which P-values of less than .05 were 
considered to indicate statistical significance.
3  | RESULTS
3.1 | Fluorescence analysis
The mean fluorescence signal intensity increased by 1.2 ± 0.3 at T1 
showing an increase in 14 out of the 20 cancer subjects.
As shown in Figure 1, the majority of patients showed an in-
crease in mean fluorescence intensity after the end of chemother-
apeutic treatment at T1, while the fluorescence intensity in some 
patients remained almost unchanged (patients 6 and 12) and even 
decreased in four patients (patients 1, 3, 13, and 15). The high-
est increases in fluorescence signal were seen in patients receiv-
ing doxorubicin, a member of the anthracycline group, which is 
known for generating its own fluorescence, which was expected 
to increase the fluorescence of the skin within these investiga-
tions. Accordingly, an average increase of 1.3 ± 0.1 was assessed 
for patients receiving doxorubicin (patients 4, 9, 17, 19, and 20). A 
TA B L E  1   Chemotherapeutics applied in the individual patients
Patient number Chemotherapeutic substance
1 Irinotecan/folinic acid/fluorouracil
2 Paclitaxel
3 Docetaxel
4 Cyclophosphamide/doxorubicin/vincristine
5 Docetaxel
6 Bortezomib/pegylated liposomal doxorubicin
7 Carboplatin/paclitaxel
8 Pegylated liposomal doxorubicin
9 Cyclophosphamide/pegylated liposomal 
doxorubicin/vincristine
10 Paclitaxel/cetuximab
11 Protein-bound paclitaxel/gemcitabine
12 Protein-bound paclitaxel/gemcitabine
13 Ifosfamide/epirubicin
14 Protein-bound paclitaxel/gemcitabine
15 Protein-bound paclitaxel/gemcitabine
16 Protein-bound paclitaxel/gemcitabine
17 Doxorubicin/dacarbazine
18 Cyclophosphamide/epirubicin
19 Doxorubicin/dacarbazine
20 Doxorubicin/dacarbazine
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minor mean increase in fluorescence by a factor of 1.1 ± 0.1 was 
observed in patients receiving pegylated liposomal doxorubicin 
(Caelix®) (patients 6 and 8). One explanation for this may be a 
minor release of doxorubicin in the liposomally encapsulated form. 
Patients treated with the doxorubicin-related chemotherapeutic 
agent epirubicin, which is also known to have autofluorescent 
properties, also showed a small increase in fluorescence (patient 
18). The single, distinct decrease in fluorescence was found in one 
patient of the anthracycline group after treatment with epirubicin 
(patient 13), which can only be explained by differences of the in-
dividual metabolism and kinetics.
Patients who received chemotherapeutics of the alkaloids group 
(eg, paclitaxel, docetaxel, nab-pablictaxel, or topotecan) showed a 
mean increase in the fluorescence of the skin by a factor of 1.3 ± 0.2 
despite the lack of fluorescence of the drugs themselves within the 
measurement time points 1 hour after termination of the infusion of 
the chemotherapeutic agents. Patients treated with the chemother-
apy drug nab-paclitaxel (abraxane, patients 11, 12, 14, 15, and 16) 
showed hardly any change in the fluorescence signal at the end of 
treatment (mean change 1.1 ± 0.1).
Conflicting results of skin fluorescence observed in two pa-
tients of the alkaloids group (patients 1 and 3) after administration 
of the chemotherapy with fluorouracil and docetaxel, can only be 
explained by the individual metabolism and kinetics.
3.2 | SERRDS analysis: Carotenoids
Healthy subjects showed a mean SERRDS carotenoid intensity at 
1136.4 a.u., which was significantly higher (P < .001) than cancer 
subjects before chemotherapy at Tbase with a mean SERRDS carot-
enoid intensity of 435.6 a.u. (Figure 2).
As shown in Figure 3, the intensity of the SERRDS signals, 
representing the concentration of carotenoids, decreases in 
the majority of patients (13 out of 20) after administration of 
chemotherapy.
Patients receiving anthracyclines showed a mean decrease in 
SERRDS signal intensity of carotenoids of 32.8 a.u., while a mean 
decrease of SERRDS signal intensity in patients receiving alkaloids 
was found at 21.6 a.u. (Figure 4).
Furthermore, it can be stated that a higher decrease in SERRDS 
intensity can be observed in patients who have already been che-
motherapeutically treated at an earlier stage compared to patients 
receiving chemotherapy for the first time.
The degree of carotenoid degradation, which correlates with the 
decrease in SERRDS intensity, appears to reflect the individual state 
of the skin's antioxidant protection system, which may be dependent 
on the stage of tumor development, number of prior chemothera-
peutic treatments, and lifestyle, including an antioxidants containing 
diet.
F I G U R E  1   Mean changes in normalized fluorescence intensities 
in each subject at basement measurements (Tbase, black squares) 
and after completion of intravenous administration of respective 
chemotherapeutic agent (T1, gray triangles). Shown are the 
calculated mean values of the fluorescence intensities of the left 
and right thenar eminence
F I G U R E  2   Boxplot of SERRDS carotenoid signal intensities in 
cancer subjects prior to the first cycle of chemotherapy at Tbase and 
healthy subjects showing a significant difference. Cancer subjects 
received no chemotherapy 4 weeks prior to the measurements at 
Tbase
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4  | DISCUSSION
In summary, the applied SERRDS measurements showed excretion 
of intravenous chemotherapeutic agents on the skin surface by si-
multaneously analyzing the carotenoid antioxidants and the fluores-
cence in the skin. The measurement system could be used for the 
indication to initiate a prevention strategy of cutaneous toxicities in 
the form of topical application of antioxidants.29,30
The results obtained show that some of the fluorescence-ac-
tive chemotherapeutic agents, for example, doxorubicin or epi-
rubicin can be detected due to enhanced skin fluorescence as 
expected.31
The direct detection and identification of all fluorescence-free 
chemotherapeutic agents in the skin using SERRDS was not 
observed within this study and can be subjected to further 
investigations.
Nevertheless, indirect measurement of chemotherapeutic 
agents on the skin surface is possible by SERRDS measurements of 
epidermal carotenoid antioxidants, which are diminished by interac-
tion with the chemotherapeutic agents. This confirms the assump-
tion that topically applied chemotherapeutic agents that reach the 
skin surface through systemic administration by sweat or sebum are 
F I G U R E  3   Mean changes in 
SERRDS signal intensities of cutaneous 
carotenoids at basement measurements 
(black squares) and after intravenous 
chemotherapy administration (gray 
triangles). Shown are the calculated 
mean values of the SERRDS carotenoid 
intensities of the left and right thenar 
eminence
F I G U R E  4   Mean SEERDS carotenoid signals in patients 
receiving chemotherapy with anthrycaclins and alkaloids. Both 
groups show an overall decrease in SERRDS signal intensities. The 
error bars represent the 95% confidence interval
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able to induce oxidative stress conditions in the skin.32 The gener-
ated radicals react as topically applied with the skin's antioxidants 
in the stratum corneum, which are subsequently decreased. By re-
ducing the level of antioxidants, the protective function of the skin 
is weakened and the induction of skin damage, inflammation, or skin 
toxicity, as shown for the hand-foot syndrome, can increase with 
each chemotherapeutic cycle.
The distinct variation in carotenoid concentration between sub-
jects is due to interindividual differences in dietary behavior and 
lifestyle, as known from a number of other studies conducted in this 
field.33-38
Furthermore, it can be stated that cancer subjects already show 
significantly lower SERRDS carotenoid intensities before chemo-
therapy treatment compared to healthy subjects. This can be due 
to the cancerous disease itself and associated emotional burden and 
stress,39-41 due to co-medication or even to prior chemotherapeuti-
cal treatments at an earlier stage.
The level of carotenoid degradation after chemotherapy that 
correlates with the decrease in SERRDS intensity appears to re-
flect the individual state of the skin's antioxidant protection sys-
tem, which may be dependent on the stage of tumor development, 
number of prior chemotherapeutic treatments, lifestyle, and anti-
oxidant diet.
Interestingly, patients who received chemotherapy for the first 
time showed a higher increase in fluorescence intensity. This may 
be due to the fact that with each chemotherapy cycle, depending on 
dosage and cycle intervals, a portion of the chemotherapeutic agent 
remains in the skin, which serves as a reservoir and thus leads to 
increased baseline fluorescence intensity.
This measurement setting could be of use in future studies in-
vestigating, for example, disruptive effects on the skin barrier subse-
quent to chemotherapy. Changes in the lipid/keratin concentration 
of the stratum corneum after completion of the systemic adminis-
tration of the chemotherapeutic agents can serve as an additional 
indirect parameter of the influence of the chemotherapeutic agents 
on the barrier function of the stratum corneum. For optimal deter-
mination of lipids and keratin whose Raman signals are broadband 
(around 200 cm−1),42 other excitation wavelengths should be used 
for improved evaluation of the lipid/keratin-related SERRDS signals 
in further studies.
Such a system could be of great importance not only for the 
investigation of development of dermal side effects of patients 
under chemotherapy but for all types of applications and skin dis-
eases that can possibly lead to stratum corneum-related barrier 
damage.
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